epirubicin has been researched along with Invasiveness, Neoplasm in 89 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 15 (16.85) | 18.2507 |
| 2000's | 28 (31.46) | 29.6817 |
| 2010's | 38 (42.70) | 24.3611 |
| 2020's | 8 (8.99) | 2.80 |
| Authors | Studies |
|---|---|
| Audenet, F; Brunelle, S; Compérat, E; Houédé, N; Lanz, C; Larré, S; Masson-Lecomte, A; Méjean, A; Neuzillet, Y; Pignot, G; Rollin, P; Roumiguié, M; Rouprêt, M; Xylinas, E | 1 |
| Allory, Y; Audenet, F; Leon, P; Loriot, Y; Masson-Lecomte, A; Neuzillet, Y; Pradère, B; Roumiguié, M; Roupret, M; Saint, F; Seisen, T; Traxer, O; Xylinas, E | 1 |
| Niu, X; Wang, T; Zhong, B | 1 |
| Brummelhuis, ISG; Crezee, J; Witjes, JA | 1 |
| Chen, L; Fu, Y; He, J; Liu, Z; Wang, S; Xia, T; Yao, N; Zhu, Y | 1 |
| El-Kappany, H; El-Nahas, AR; El-Shabrawy, M; Harraz, AM; Osman, Y | 1 |
| Bi, XJ; Cai, F; Fu, M; He, SY; Jia, LQ; Jing, M; Kong, L; Li, XT; Liu, JJ; Liu, XZ; Yao, XM; Zhang, L | 1 |
| Chen, J; Chen, L; Huang, B; Huang, G; Li, W; Mao, X | 1 |
| Adriaenssens, E; Angrand, PO; Bidan, N; Chopin, V; Lagadec, C; Le Bourhis, X; Meignan, S; Toillon, RA; Völkel, P; Winter, M | 1 |
| Liu, Y; Shang, D; Song, B | 1 |
| Chen, D; Huang, H; Lu, Y; Yang, H | 1 |
| Cozar-Olmo, JM; Fernandez-Gomez, JM; Juárez, A; Martínez-Piñeiro, L; Palou, J; Unda-Urzaiz, M | 1 |
| Liu, S; Qin, Y; Song, X; Sun, Z; Wang, Y; Yang, J; Yu, K; Zhang, S; Zhou, X | 1 |
| Fu, H; Pan, Y; Zhang, J; Zhang, X | 1 |
| Chen, J; Chen, L; Fan, W; Huang, B; Lin, H; Qiu, S; Wang, H; Yao, Z; Zheng, J | 1 |
| Chen, W; Cui, W; Fan, W; Li, J; Lian, F; Liu, Y; Shen, L; Wang, Y; Zhao, Y | 1 |
| Cai, FY; Fu, M; Gong, XQ; Jing, M; Ju, RJ; Kong, L; Li, XT; Liu, JJ; Tang, W; Yao, XM | 1 |
| Huang, L; Meng, L; Xu, Y; Zhang, W | 1 |
| Aittomäki, K; Blomqvist, C; Carpén, O; Fagerholm, R; Heikkilä, P; Heikkinen, T; Khan, S; Korpela, T; Nevanlinna, H | 1 |
| Bailey, IS; Byrne, JP; Curtis, NJ; Kelly, JJ; Noble, F; Underwood, TJ | 1 |
| Hayashi, N; Kajiura, Y; Matsuda, N; Nakamura, S; Ohde, S; Suzuki, K; Tsunoda, H; Yagata, H; Yamauchi, H; Yoshida, A | 1 |
| Cartei, F; Cocuzza, P; Colosimo, C; Fiorica, F; Greco, C; Mazzotti, V; Pedriali, M; Stefanelli, A; Taibi, R; Ursino, S | 1 |
| Ju, RJ; Li, XT; Li, XY; Liu, L; Lu, WL; Shi, JF; Sun, MG; Zeng, F; Zhang, CX; Zhao, WY; Zhou, J | 1 |
| Brausi, MA; de Reijke, TM; Kirkels, WJ; Oddens, JR; Oosterlinck, W; Prescott, S; Sylvester, RJ; van Andel, G; van de Beek, C; Witjes, JA | 1 |
| Anderson, A; Davidenko, I; Deptala, A; Donehower, RC; Dubey, S; Harrison, M; Iveson, T; Jiang, Y; Lakshmaiah, K; Loh, E; Nirni, S; Oliner, KS; Tang, R; Thomas, A; Tjulandin, S; Zhu, M | 1 |
| Abraham, J; Basu, B; Brenton, J; Earl, H; Freeman, S; Gounaris, I; Hatcher, H; Hosking, K; Iddawela, M; Jimenez-Linan, M; Moyle, P; Parkinson, C; Sayal, K | 1 |
| Hashimoto, Y; Hatakeyama, S; Hosogoe, S; Imai, A; Koie, T; Mori, K; Ohyama, C; Tobisawa, Y; Yamamoto, H; Yoneyama, T | 1 |
| Ju, RJ; Li, XT; Li, XY; Lu, WL; Mu, LM; Shi, JF; Sun, MG; Yan, Y; Zeng, F; Zhao, Y | 1 |
| Au, HJ; Bies, RR; Carandang, D; Cass, CE; Clemons, M; Damaraju, S; Damaraju, VL; Hanson, J; Joy, AA; King, K; Koski, S; Kuzma, M; Mackey, JR; Pituskin, E; Prado, CM; Sawyer, MB; Scarfe, AG; Smylie, M; Tonkin, K; Vos, LJ | 1 |
| Aaltomaa, S; Boström, P; Hellström, P; Järvinen, R; Kaasinen, E; Leskinen, M; Liukkonen, T; Marttila, T; Raitanen, M; Rintala, E; Seppänen, M; Tammela, T | 1 |
| Du, J; Fan, L; Jiang, J; Liang, Q; Liu, J; Ming, J; Zhang, Y; Zhong, L | 1 |
| Cui, H; Jiang, R; Li, X; Lin, X; Liu, C; Tao, R; Tian, S; Zhuang, H; Zhuo, C | 1 |
| Alunni-Fabbroni, M; Andergassen, U; Camara, O; de Gregorio, N; Decker, T; Fasching, PA; Fehm, TN; Friedl, TWP; Heinrich, G; Jaeger, B; Janni, W; Mahner, S; Ober, A; Pantel, K; Rack, BK; Schneeweiss, A; Schochter, F; Schramm, A; Trapp, E | 1 |
| Adell, L; Bendahl, PO; Davidsson, T; Grabe, M; Gudjónsson, S; Hagberg, G; Larsson, B; Liedberg, F; Månsson, W; Merdasa, F; Olsson, R; Richthoff, J | 1 |
| Goya, N; Hashimoto, Y; Iida, S; Kobayashi, H; Kondo, T; Tanabe, K | 1 |
| Airoldi, M; Beatrice, F; Condello, C; Gabriele, AM; Garzaro, M; Giordano, C; Pecorari, G; Raimondo, L | 1 |
| Gu, YJ; Guo, X; Guo, Y; Lu, H; Ma, X; Pang, Z; Wang, B | 1 |
| Arii, S; Ikai, I; Kojiro, M; Kudo, M; Makuuchi, M; Matsuyama, Y; Takayasu, K | 1 |
| Atkins, CD | 1 |
| Bertheau, P; Brain, E; Delaloge, S; Espié, M; Guinebretière, JM; Marty, M; Mathieu, MC; Pierga, JY; Savignoni, A; Sigal-Zafrani, B; Spielmann, M | 1 |
| Ebert, M; Grenacher, L; Lordick, F; Moehler, M; Röcken, C; Schumacher, G | 1 |
| Ah-See, ML; Beresford, MJ; Collins, DJ; d'Arcy, JA; Li, SP; Makris, A; Padhani, AR; Stirling, JJ; Taylor, NJ | 1 |
| Song, ST | 1 |
| Akaza, H; Hinotsu, S; Koga, H; Kume, H; Nagamori, S; Naito, S; Nasu, Y; Noguchi, S; Ozono, S; Samma, S; Sumiyoshi, Y; Tanaka, Y; Terai, A; Tomita, Y; Tsushima, T; Uemura, H; Yamaguchi, A | 1 |
| Han, B; Liu, H; Ruan, Y; Sun, X; Xia, S; Xue, S | 1 |
| Beck, T; Camara, O; du Bois, A; Fasching, PA; Fett, W; Harbeck, N; Hasmüller, S; Höss, C; Kahlert, S; Konecny, GE; Kreienberg, R; Kühn, T; Lebeau, A; Loibl, S; Mehta, KM; Müller, V; Stickeler, E; Untch, M; von Minckwitz, G | 1 |
| Cao, M; Chen, HG; Ma, CK; Ma, J; Xue, W | 1 |
| Kordek, R; Kusinska, R; Majsterek, I; Przybylowska-Sygut, K; Stanczyk, M | 1 |
| Ieda, N; Pirovano, C; Siesto, G; Vitobello, D | 1 |
| Chow, LW; Glück, S; Im, SA; Lee, MH; Ng, TY; Toi, M; Tung, SY; Yip, AY | 1 |
| Brundage, M; Chin, JL; Lukka, H; Markman, BR; Segal, R; Winquist, E | 1 |
| Bisagni, G; Camisa, R; Canaletti, R; Carlini, P; Cocconi, G; Cognetti, F; Di Costanzo, F; Gamboni, A; Gasperoni, S; Porrozzi, S; Pucci, F; Rodinò, C; Ruggeri, EM; Zironi, S | 1 |
| Habuchi, T; Kamoto, T; Nakashima, M; Nishiyama, H; Ogawa, O; Yagihashi, Y; Yamamoto, S | 1 |
| Bielawski, KP; Bosse, U; Schlotter, CM; Vogt, U | 1 |
| Barats, JC; Bonneterre, J; Campone, M; Chapelle-Marcillac, I; Fargeot, P; Goudier, MJ; Guastalla, JP; Lortholary, A; Monnier, A; Namer, M; Roché, H; Schraub, S; Van Praagh, I | 1 |
| Bartsch, R; Gnant, MF; Hussian, D; Jakesz, R; Locker, GJ; Pluschnig, U; Sevelda, U; Steger, GG; Wenzel, C; Zielinski, CC | 1 |
| Fujimoto, K; Fukushima, M; Hirao, Y; Matsui, Y; Nishiyama, H; Ogawa, O; Ohshima, S; Ono, Y; Teramukai, S; Watanabe, J | 1 |
| Ito, S; Kariya, S; Moriki, T; Murata, Y; Nishioka, A; Ogawa, Y; Ohnishi, T; Yoshida, S | 1 |
| Alliot, C | 1 |
| Hitzl, W; Peintinger, F; Prokop, E; Reitsamer, R | 1 |
| Amici, S; Gasparini, G; Gattuso, D; Gion, M; Longo, R; Sarmiento, R; Zancan, M | 1 |
| Alberti, S; Angelucci, D; Cianchetti, E; Ficorella, C; Iacobelli, S; Lattanzio, R; Marchetti, P; Natoli, C; Piantelli, M; Ricevuto, E; Tinari, N | 1 |
| Franke, FE; Hackethal, A; Münstedt, K; Von Georgi, R; Woenckhaus, J | 1 |
| Fujii, M; Hirota, S; Maruta, T; Matsumoto, S; Nakanishi, K; Ohno, Y; Saigo, K; Sugimura, K; Takenaka, D; Yoshikawa, T | 1 |
| Angellier, E; Berdah, JF; Buyse, M; Fabbro, M; Greget, S; Herait, P; Jehl, V; Laplaige, P; Piedbois, P; Priou, F; Serin, D; Teissier, E; Valenza, B | 1 |
| Ren, YL; Shen, L; Wang, HY; Yang, WT | 1 |
| Ames, FC; Babiera, GV; Feig, BW; Francis, A; Gilcrease, MZ; Hunt, KK; Kuerer, HM; Meric-Bernstam, F; Ross, MI; Shen, J | 1 |
| Aitini, E; Ardizzoia, A; Arnoldi, E; Barni, S; Barone, C; Beretta, GD; Bertetto, O; Carnaghi, C; Cascinu, S; Cassano, A; Catalano, V; Chiara, S; Cortesi, E; Floriani, I; Foa, P; Frontini, L; Gasparini, G; Giordani, P; Labianca, R; Mansutti, M; Mosconi, S; Nardi, M; Piazza, E; Pozzo, C; Pucci, F; Rabbi, C; Ravaioli, A; Rimassa, L; Rota, S; Santoro, A; Silva, RR; Sobrero, A; Torri, V | 1 |
| Hagihara, A; Ikeda, M; Iwasa, S; Kojima, Y; Morizane, C; Okusaka, T; Ueno, H | 1 |
| Baldan, A; Burra, P; Cardin, R; Cillo, U; Cristofori, C; Farinati, F; Giacomin, A; Girardi, L; Pivetta, G; Ragazzi, R; Sergio, A | 1 |
| Caris, CT; de Bruin, MJ; Hendricksen, K; Idema, JG; Janzing-Pastors, MH; Kums, JJ; van Vierssen Trip, OB; Vergunst, H; Witjes, JA; Witjes, WP | 1 |
| Bartoletti, R; Boddi, V; Cai, T; Mazzoli, S; Mondaini, N; Nesi, G; Tinacci, G; Zini, E | 1 |
| Chuchkova, M; Damianov, C; Koleva, P; Terziev, T | 1 |
| Ikenaga, M; Kikkawa, N; Kobayashi, K; Mishima, H; Morita, T; Shin, E; Takatsuka, Y; Tamaki, Y; Touno, T; Yagyu, T | 1 |
| Kobayashi, H; Obata, K | 1 |
| Cevoli, R; Cocimano, V; Marino, G; Marten Perolino, R | 1 |
| Chionis, HS; Dauaher, HH; Melekos, MD; Paranychianakis, GS | 1 |
| Fujinaga, H; Kume, K; Matsuzaka, T; Ono, E; Wakasugi, K; Yano, M | 1 |
| Kawaguchi, T; Nishimura, S; Takahashi, N | 1 |
| Akyüz, C; Berberoğlu, S; Büyükpamukçu, M | 1 |
| Ali-el-Dein, B; Aly, AN; Ashamallah, A; el-Baz, M; Shamaa, S | 1 |
| Hubmer, G; Lehnert, M; Pummer, K; Stettner, H | 1 |
| Kroeger, N; Kupper, H; Lehnert, M; Mross, K; Schueller, J; Thuerlimann, B | 1 |
| Chauvergne, J; Fervers, B; Fondrinier, E; Guastalla, JP; Haie-Meder, C; Lhommé, C; Resbeut, M | 1 |
| Griffiths, TR; Hall, RR; Lunec, J; Marsh, C; Neal, DE; Qureshi, KN; Roberts, JT; Robinson, MC | 1 |
| Fischer, C; Lehmann, J; Loch, T; Pinkenburg, FA; Retz, M; Seppelt, U; Stöckle, M; Timm, KJ; Trocha, C; Wellek, S | 1 |
| Baba, K; Fukuda, M; Matsuda, M; Matsuoka, Y; Miyayama, H; Nagao, K; Nishimura, R; Yamashita, H | 1 |
| Furukawa, Y; Hayashi, J; Hidaka, N; Kato, M; Ohashi, N; Sanda, M; Yajima, Y | 1 |
| Newling, DW | 1 |
6 review(s) available for epirubicin and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Nucleolar and Spindle Associated Protein 1 (NUSAP1) Inhibits Cell Proliferation and Enhances Susceptibility to Epirubicin In Invasive Breast Cancer Cells by Regulating Cyclin D Kinase (CDK1) and DLGAP5 Expression.
Topics: Apoptosis; Breast Neoplasms; CDC2 Protein Kinase; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclin D; Drug Resistance, Neoplasm; Epirubicin; Female; Humans; MCF-7 Cells; Microtubule-Associated Proteins; Neoplasm Invasiveness; Neoplasm Proteins; RNA, Messenger; Transcriptome | 2018 |
Anaplastic thyroid cancer: a case report of a long term survival patient and review of literature data.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Epirubicin; Humans; Male; Middle Aged; Neoplasm Invasiveness; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Thyroidectomy; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Evaluating the efficacy and safety of intravesical chemotherapies for non-muscle invasive bladder cancer: a network meta-analysis.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; BCG Vaccine; Deoxycytidine; Disease Progression; Epirubicin; Female; Gemcitabine; Humans; Isoniazid; Male; Middle Aged; Mitomycin; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Odds Ratio; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms | 2016 |
[Diagnosis and treatment of gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Signet Ring Cell; Cisplatin; Endoscopy, Digestive System; Epirubicin; Esophagectomy; Fluorouracil; Gastrectomy; Gastric Mucosa; Humans; Laparoscopy; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Neoplasm, Residual; Stomach Neoplasms; Tomography, X-Ray Computed | 2010 |
[A case report of a young patient with invasive bladder cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Epirubicin; Humans; Male; Methotrexate; Neoplasm Invasiveness; Prostatic Neoplasms; Urinary Bladder Neoplasms; Urinary Diversion | 2003 |
[Standards, options and recommendations: concomitant radiochemotherapy for cancer of the cervix: a critical analysis of the literature and update of SOR].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Epirubicin; Female; Fluorouracil; Humans; Hydroxyurea; Lymphatic Metastasis; Multicenter Studies as Topic; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Practice Guidelines as Topic; Prognosis; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome; Uterine Cervical Neoplasms | 1999 |
31 trial(s) available for epirubicin and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Single Versus Maintenance Intravesical Chemotherapy for the Prevention of Bladder Recurrence after Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Randomized Clinical Trial.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Drug Administration Schedule; Epirubicin; Female; Humans; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Nephroureterectomy; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 2019 |
Randomized controlled trial of late-course concurrent versus sequential chemoradiotherapy after mastectomy and axillary surgery in locally advanced breast cancer.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Chemoradiotherapy; Cyclophosphamide; Docetaxel; Dose Fractionation, Radiation; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Lymph Node Excision; Lymph Nodes; Mastectomy; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Taxoids; Treatment Outcome | 2017 |
Evaluation of the effects of intra-arterial chemotherapy combined with intravesical chemotherapy against intravesical chemotherapy alone after transurethral resection of bladder tumor in T1-staged Grade 3 bladder cancer.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Epirubicin; Female; Follow-Up Studies; Humans; Injections, Intra-Arterial; Male; Middle Aged; Muscle Neoplasms; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Survival Rate; Urinary Bladder Neoplasms | 2019 |
The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
Topics: Age Factors; Aged; Aged, 80 and over; BCG Vaccine; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cystectomy; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Proportional Hazards Models; Risk Assessment; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms | 2014 |
Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Epirubicin; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Proportional Hazards Models; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2014 |
Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Endometrial Neoplasms; Epirubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Ovarian Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2015 |
Intravesical Bacillus Calmette-Guérin Versus Combination of Epirubicin and Interferon-α2a in Reducing Recurrence of Non-Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Antibiotics, Antineoplastic; BCG Vaccine; Epirubicin; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Recombinant Proteins; Survival Analysis; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms | 2016 |
Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoplasm Invasiveness; Neoplastic Cells, Circulating; Prevalence; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Taxoids; Young Adult | 2017 |
Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Combined Modality Therapy; Epirubicin; Female; Humans; Male; Neoplasm Invasiveness; Postoperative Care; Prospective Studies; Time Factors; Urinary Bladder Neoplasms; Urologic Surgical Procedures | 2009 |
Induction chemotherapy with cisplatin and epirubicin followed by radiotherapy and concurrent cisplatin in locally advanced nasopharyngeal carcinoma observed in a non-endemic population.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Cisplatin; Epirubicin; Female; Humans; Male; Nasopharyngeal Neoplasms; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Treatment Outcome | 2009 |
A randomized phase II study of CEOP with or without semustine as induction chemotherapy in patients with stage IE/IIE extranodal NK/T-cell lymphoma, nasal type in the upper aerodigestive tract.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Epirubicin; Female; Humans; Lymphoma, Extranodal NK-T-Cell; Male; Middle Aged; Neoplasm Invasiveness; Nose Neoplasms; Pharyngeal Neoplasms; Prednisone; Prognosis; Radiation Injuries; Semustine; Survival Rate; Vincristine; Young Adult | 2009 |
A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Celecoxib; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; France; Humans; In Situ Hybridization, Fluorescence; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Pyrazoles; Receptor, ErbB-2; Sulfonamides; Taxoids; Therapeutics; Time Factors; Trastuzumab | 2010 |
Maintenance therapy with bacillus Calmette-Guérin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Aged; Antineoplastic Agents; BCG Vaccine; Combined Modality Therapy; Cystectomy; Disease-Free Survival; Epidemiologic Methods; Epirubicin; Female; Humans; Male; Middle Aged; Mycobacterium bovis; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Treatment Outcome; Urinary Bladder Neoplasms; Young Adult | 2011 |
Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cohort Studies; Cyclophosphamide; Epirubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Remission Induction; Survival Rate; Trastuzumab; Treatment Outcome; Young Adult | 2011 |
[Evaluation of the efficacy and safety of intravesical instillation with gemcitabine after first-line intravesical chemotherapy failure in the treatment of non-muscle-invasive bladder cancer].
Topics: Administration, Intravesical; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Mitomycin; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2011 |
Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II - III invasive breast cancer: the OOTR-N001 study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Celecoxib; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Phenobarbital; Prospective Studies; Pyrazoles; Receptor, ErbB-2; Sulfonamides; Taxoids | 2013 |
Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Confidence Intervals; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Italy; Leucovorin; Male; Methotrexate; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Probability; Prognosis; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2003 |
Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Humans; Immunohistochemistry; Lymph Nodes; Lymphatic Metastasis; Mastectomy; Maximum Tolerated Dose; Menopause; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Risk Assessment; Survival Rate; Tamoxifen; Treatment Outcome | 2004 |
Preoperative chemotherapy with epidoxorubicin, docetaxel and capecitabine plus pegfilgrastim in patients with primary breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Epirubicin; Female; Filgrastim; Fluorouracil; Glucuronates; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Pilot Projects; Polyethylene Glycols; Preoperative Care; Prospective Studies; Receptor, ErbB-2; Recombinant Proteins; Taxoids; Treatment Outcome | 2005 |
Pathological complete response rates comparing 3 versus 6 cycles of epidoxorubicin and docetaxel in the neoadjuvant setting of patients with stage II and III breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Glucuronates; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Prospective Studies; Receptor, ErbB-2; Remission Induction; Taxoids; Treatment Outcome | 2005 |
Gefitinib (ZD1839) combined with weekly epirubicin in patients with metastatic breast cancer: a phase I study with biological correlate.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Epirubicin; ErbB Receptors; Female; Gefitinib; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Quinazolines; Receptor, ErbB-2 | 2005 |
Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 rando
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Feasibility Studies; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Survival Rate; Taxoids; Treatment Outcome | 2007 |
Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Stomach Neoplasms; Survival Analysis | 2007 |
Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Cystoscopy; Drug Administration Schedule; Epirubicin; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2008 |
Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; BCG Vaccine; Double-Blind Method; Drug Synergism; Epirubicin; Female; Humans; Male; Middle Aged; Neoplasm Invasiveness; Prospective Studies; Risk Factors; Time Factors; Urinary Bladder Neoplasms | 2008 |
Combined immunochemotherapy (CEP, M-VEP + BCG) in the treatment of invasive bladder tumors.
Topics: Administration, Intravesical; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Cisplatin; Combined Modality Therapy; Epirubicin; Etoposide; Female; Follow-Up Studies; Humans; Immunotherapy, Active; Lomustine; Male; Methotrexate; Middle Aged; Neoplasm Invasiveness; Prednimustine; Urinary Bladder Neoplasms; Vinblastine | 1994 |
Results of adjuvant chemotherapy for invasive urothelial cancer with lymph-node metastasis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Doxorubicin; Epirubicin; Etoposide; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Kidney Pelvis; Longitudinal Studies; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Neoplasm Invasiveness; Survival Rate; Ureteral Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms; Vinblastine | 1994 |
Intravesical 4'-epi-doxorubicin (epirubicin) versus bacillus Calmette-Guérin. A controlled prospective study on the prophylaxis of superficial bladder cancer.
Topics: Administration, Intravesical; Aged; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Combined Modality Therapy; Cystitis; Epirubicin; Female; Follow-Up Studies; Humans; Male; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Remission Induction; Urinary Bladder Neoplasms | 1993 |
Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Chemotherapy, Adjuvant; Disease Progression; Doxorubicin; Epirubicin; Female; Humans; Male; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Urinary Bladder Neoplasms | 1997 |
Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
Topics: Aged; Androgen Antagonists; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Epirubicin; Flutamide; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Orchiectomy; Prospective Studies; Prostatic Neoplasms; Software; Treatment Outcome | 1997 |
Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Blood Pressure; Breast Neoplasms; Calcium Channel Blockers; Drug Resistance, Neoplasm; Epirubicin; Female; Humans; Middle Aged; Neoplasm Invasiveness; Treatment Outcome; Verapamil | 1998 |
52 other study(ies) available for epirubicin and Invasiveness, Neoplasm
| Article | Year |
|---|---|
[Intravesical adjuvant regimen of epitubicin for intermediate risk NMIBC: Feasability study from CC-AFU vessie].
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Antibiotics, Antineoplastic; BCG Vaccine; Clinical Protocols; COVID-19 Drug Treatment; Epirubicin; Female; Humans; Male; Mitomycin; Neoplasm Invasiveness; Retrospective Studies; Urinary Bladder Neoplasms | 2022 |
[Guidelines from the cancer committee of the French Association of Urology (CC-AFU) for adequate intravesical instillations of Mitomycin C, Epirubicin, and BCG for non-muscle invasive bladder cancer].
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Epirubicin; Female; Humans; Male; Mitomycin; Neoplasm Invasiveness; Urinary Bladder Neoplasms; Urology | 2022 |
Molecular classification of patients with NMIBC predicts the efficacy of intravesical chemotherapy with pirarubicin, pharmorubicin and gemcitabine-immunohistochemistry-based classification.
Topics: Administration, Intravesical; Anthracyclines; Antibiotics, Antineoplastic; Deoxycytidine; Doxorubicin; Epirubicin; Gemcitabine; Humans; Immunohistochemistry; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2022 |
Evaluation of thermal dose effect in radiofrequency-induced hyperthermia with intravesical chemotherapy for nonmuscle invasive bladder cancer.
Topics: Combined Modality Therapy; Epirubicin; Humans; Hyperthermia, Induced; Mitomycin; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2023 |
Long non-coding RNA NONHSAT101069 promotes epirubicin resistance, migration, and invasion of breast cancer cells through NONHSAT101069/miR-129-5p/Twist1 axis.
Topics: Breast Neoplasms; Cell Movement; Drug Resistance, Neoplasm; Epirubicin; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; MicroRNAs; Neoplasm Invasiveness; Nuclear Proteins; RNA, Long Noncoding; Twist-Related Protein 1 | 2019 |
Enhanced antitumor efficacy using epirubicin and schisandrin B co-delivery liposomes modified with PFV via inhibiting tumor metastasis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Chick Embryo; Chorioallantoic Membrane; Cyclooctanes; Epirubicin; Female; Humans; Lignans; Liposomes; Lung Neoplasms; Mice; Neoplasm Invasiveness; Polycyclic Compounds; Xenograft Model Antitumor Assays | 2020 |
Intra-arterial chemotherapy combined with intravesical chemotherapy compared with intravesical BCG immunotherapy retrospectively in high-risk non-muscle-invasive bladder cancer after transurethral resection of the bladder tumor.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cystectomy; Doxorubicin; Epirubicin; Female; Humans; Immunotherapy; Infusions, Intra-Arterial; Male; Middle Aged; Neoplasm Invasiveness; Retrospective Studies; Risk Factors; Urinary Bladder Neoplasms | 2021 |
Vimentin Promotes the Aggressiveness of Triple Negative Breast Cancer Cells Surviving Chemotherapeutic Treatment.
Topics: Animals; Cell Line, Tumor; Cell Movement; Cyclophosphamide; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Therapy; Epirubicin; Epithelial-Mesenchymal Transition; Female; Humans; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Paclitaxel; Triple Negative Breast Neoplasms; Vimentin; Zebrafish | 2021 |
Epirubicin suppresses proliferative and metastatic potential by downregulating transforming growth factor-β-induced expression in urothelial carcinoma.
Topics: Carcinoma; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation; Epirubicin; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; RNA, Messenger; Transforming Growth Factor beta; Up-Regulation; Urologic Neoplasms; Urothelium | 2018 |
Update on the role of endovesical chemotherapy in nonmuscle-invasive bladder cancer.
Topics: Administration, Intravesical; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Combined Modality Therapy; Doxorubicin; Epirubicin; Humans; Mitomycin; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Practice Guidelines as Topic; Urinary Bladder Neoplasms | 2018 |
Emodin inhibits epithelial‑mesenchymal transition and metastasis of triple negative breast cancer via antagonism of CC‑chemokine ligand 5 secreted from adipocytes.
Topics: Adipocytes; Adult; Animals; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemokine CCL5; Coculture Techniques; Emodin; Epirubicin; Epithelial-Mesenchymal Transition; Female; Humans; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Signal Transduction; Triple Negative Breast Neoplasms | 2018 |
Intra-arterial chemotherapy combined with intravesical chemotherapy is effective in preventing recurrence in non-muscle invasive bladder cancer.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Chemotherapy, Adjuvant; Cystectomy; Epirubicin; Female; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Retrospective Studies; Urinary Bladder Neoplasms | 2019 |
Development of R
Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Artemisinins; Biological Transport; Carcinoma, Non-Small-Cell Lung; Cell Adhesion; Drug Liberation; Epirubicin; Humans; Lipid Bilayers; Liposomes; Lung Neoplasms; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Polyethylene Glycols; Xenograft Model Antitumor Assays | 2019 |
Incidence of interstitial pneumonitis in breast cancer patients treated with pegylated liposomal doxorubicin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; China; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Humans; Incidence; Lung Diseases, Interstitial; Middle Aged; Neoplasm Invasiveness; Polyethylene Glycols; Prognosis; Retrospective Studies | 2020 |
Eukaryotic translation initiation factor 4E (eIF4E) expression is associated with breast cancer tumor phenotype and predicts survival after anthracycline chemotherapy treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Cyclophosphamide; Cytarabine; Doxorubicin; Epirubicin; Eukaryotic Initiation Factor-4E; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Proteins; Paraffin Embedding; Phenotype; Prognosis; Protein Biosynthesis; Tissue Array Analysis; Treatment Outcome; Triple Negative Breast Neoplasms | 2013 |
The relevance of the Siewert classification in the era of multimodal therapy for adenocarcinoma of the gastro-oesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anastomotic Leak; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Databases, Factual; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Fluorouracil; Gastrectomy; Hospitals, University; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Prognosis; Prospective Studies; Stomach Neoplasms; United Kingdom | 2014 |
A nomogram for predicting locoregional recurrence in primary breast cancer patients who received breast-conserving surgery after neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Nomograms; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; ROC Curve; Survival Rate; Taxoids | 2014 |
Liposomes, modified with PTD(HIV-1) peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast; Breast Neoplasms; Celecoxib; Cell Line, Tumor; Drug Delivery Systems; Epirubicin; Female; HIV-1; Humans; Liposomes; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neovascularization, Pathologic; Peptides; Phosphatidylethanolamines; Polyethylene Glycols; Pyrazoles; Sulfonamides | 2014 |
Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma, Transitional Cell; Combined Modality Therapy; Cystectomy; Cystoscopy; Disease Progression; Disease-Free Survival; Epirubicin; Female; Follow-Up Studies; Humans; Japan; Male; Middle Aged; Natural Orifice Endoscopic Surgery; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Retrospective Studies; Survival Rate; Treatment Outcome; Urethra; Urinary Bladder Neoplasms | 2015 |
Targeting Epirubicin Plus Quinacrine Liposomes Modified with DSPE-PEG2000-C(RGDfK) Conjugate for Eliminating Invasive Breast Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Epirubicin; Female; Humans; Liposomes; Mice; Mice, Inbred BALB C; Nanocapsules; Nanoconjugates; Neoplasm Invasiveness; Particle Size; Peptides, Cyclic; Phosphatidylethanolamines; Polyethylene Glycols; Quinacrine; Treatment Outcome | 2015 |
A Uridine Glucuronosyltransferase 2B7 Polymorphism Predicts Epirubicin Clearance and Outcomes in Early-Stage Breast Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Genotype; Glucuronosyltransferase; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate | 2016 |
Evaluation of the tracing effect of carbon nanoparticle and carbon nanoparticle-epirubicin suspension in axillary lymph node dissection for breast cancer treatment.
Topics: Adenocarcinoma, Mucinous; Antibiotics, Antineoplastic; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Medullary; Case-Control Studies; Charcoal; Combined Modality Therapy; Epirubicin; Female; Follow-Up Studies; Humans; Lymph Node Excision; Lymphatic Metastasis; Middle Aged; Nanoparticles; Neoplasm Invasiveness; Neoplasm Staging; Prognosis | 2016 |
Clinical outcome of high-grade non-muscle-invasive bladder cancer: a long-term single center experience.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; BCG Vaccine; Carcinoma, Transitional Cell; Cause of Death; Chemotherapy, Adjuvant; Cohort Studies; Combined Modality Therapy; Cystectomy; Epirubicin; Female; Follow-Up Studies; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Muscle, Smooth; Neoplasm Invasiveness; Neoplasm Staging; Probability; Retrospective Studies; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms | 2009 |
Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chi-Square Distribution; Cisplatin; Combined Modality Therapy; Diagnostic Imaging; Doxorubicin; Epirubicin; Female; Humans; Iodized Oil; Liver Neoplasms; Logistic Models; Male; Middle Aged; Mitomycin; Neoplasm Invasiveness; Neoplasm Staging; Proportional Hazards Models; Prospective Studies; Surveys and Questionnaires; Survival Rate; Treatment Outcome; Zinostatin | 2010 |
Optimal chemotherapy for high-risk early-stage breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Epirubicin; Female; Humans; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Prognosis; Risk Assessment; Survival Analysis; Treatment Outcome | 2010 |
Primary human breast adenocarcinoma: imaging and histologic correlates of intrinsic susceptibility-weighted MR imaging before and during chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Contrast Media; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Image Interpretation, Computer-Assisted; In Situ Hybridization, Fluorescence; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Neoplasm, Residual; Prospective Studies; ROC Curve; Statistics, Nonparametric; Taxoids | 2010 |
[Practice and consideration on neoadjuvant therapy for early breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Methotrexate; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tumor Burden | 2010 |
2-micrometer continuous wave laser treatment for multiple non-muscle-invasive bladder cancer with intravesical instillation of epirubicin.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Combined Modality Therapy; Epirubicin; Female; Humans; Laser Therapy; Male; Middle Aged; Neoplasm Invasiveness; Urinary Bladder Neoplasms | 2011 |
Association of the Arg194Trp and the Arg399Gln polymorphisms of the XRCC1 gene with risk occurrence and the response to adjuvant therapy among Polish women with breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; DNA Repair; DNA-Binding Proteins; Doxorubicin; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Genetic Predisposition to Disease; Genotype; Humans; Immunoenzyme Techniques; Methotrexate; Neoplasm Invasiveness; Neoplasm Staging; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Risk Factors; Survival Rate; X-ray Repair Cross Complementing Protein 1 | 2013 |
Surgical outcomes of robotic radical hysterectomy after neoadjuvant chemotherapy for locally advanced cervical cancer: comparison with early stage disease.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell; Cisplatin; Dose Fractionation, Radiation; Epirubicin; Feasibility Studies; Female; Humans; Hysterectomy; Ifosfamide; Laparoscopy; Lymph Node Excision; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Prospective Studies; Radiotherapy, Adjuvant; Robotics; Safety; Treatment Outcome; Uterine Cervical Neoplasms; Vagina | 2013 |
Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Cystectomy; Doxorubicin; Epirubicin; Evidence-Based Medicine; Humans; Lymphatic Metastasis; Methotrexate; Neoplasm Invasiveness; Randomized Controlled Trials as Topic; Survival Analysis; Urinary Bladder Neoplasms; Vinblastine | 2002 |
Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Cyclophosphamide; Diphosphonates; Docetaxel; Drug Synergism; Epirubicin; Female; Fluorouracil; Humans; Ibandronic Acid; Imidazoles; In Vitro Techniques; Methotrexate; Middle Aged; Neoplasm Invasiveness; Neoplasms, Ductal, Lobular, and Medullary; Paclitaxel; Taxoids; Zoledronic Acid | 2004 |
The current status of perioperative chemotherapy for invasive bladder cancer: a multiinstitutional retrospective study in Japan.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cystectomy; Doxorubicin; Epirubicin; Female; Humans; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2005 |
Relationship between hormonal receptors, HER-2, p53 protein, Bcl-2, and MIB-1 status and the antitumor effects of neoadjuvant anthracycline-based chemotherapy in invasive breast cancer patients.
Topics: Adult; Aged; Analysis of Variance; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy, Needle; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Ki-67 Antigen; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Proto-Oncogene Proteins c-bcl-2; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tumor Suppressor Protein p53 | 2005 |
Weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Humans; Immunohistochemistry; Lymph Nodes; Lymphatic Metastasis; Mastectomy; Maximum Tolerated Dose; Menopause; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Risk Assessment; Survival Rate; Tamoxifen; Treatment Outcome | 2005 |
Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance, Neoplasm; Epirubicin; Female; Fluorouracil; Humans; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm, Residual; Prognosis; Proto-Oncogene Mas; Receptor, ErbB-2; Stereoisomerism | 2006 |
Glucocorticosteroid receptors in ovarian carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Glucocorticoids; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Ovarian Neoplasms; Prognosis; Receptors, Glucocorticoid; Survival Rate | 2006 |
Anticoagulant-induced pseudothrombocytopenia occurring after transcatheter arterial embolization for hepatocellular carcinoma.
Topics: Aged; Antibiotics, Antineoplastic; Anticoagulants; Blood Platelets; Carcinoma, Hepatocellular; Disseminated Intravascular Coagulation; Edetic Acid; Embolization, Therapeutic; Epirubicin; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Neoplasm Invasiveness; Platelet Count; Portal Vein; Thrombocytopenia | 2006 |
[Clinical and pathologic analysis of 33 cases of uterine papillary serous carcinoma].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary; Chemotherapy, Adjuvant; Cisplatin; Endometrial Neoplasms; Epirubicin; Female; Humans; Hysterectomy; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Retrospective Studies; Survival Rate; Uterine Neoplasms | 2006 |
Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Biopsy, Fine-Needle; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Doxorubicin; Epirubicin; False Negative Reactions; Feasibility Studies; Female; Fluorouracil; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Preoperative Care; Sentinel Lymph Node Biopsy; Time Factors; Ultrasonography, Mammary | 2007 |
Hepatic arterial infusion chemotherapy with epirubicin in patients with advanced hepatocellular carcinoma and portal vein tumor thrombosis.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma, Hepatocellular; Epirubicin; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Portal Vein; Retrospective Studies; Survival Analysis; Venous Thrombosis | 2007 |
Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness.
Topics: Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Enzyme-Linked Immunosorbent Assay; Epirubicin; Female; Fibroblast Growth Factor 2; Humans; Infusions, Intra-Arterial; Iodized Oil; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neovascularization, Pathologic; Prognosis; Proportional Hazards Models; Statistics, Nonparametric; Survival Rate; Urokinase-Type Plasminogen Activator; Vascular Endothelial Growth Factor A | 2008 |
[A case of advanced gastric cancer successfully treated with resection after FEP (5-FU, epirubicin, CDDP) combined chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Epirubicin; Fluorouracil; Gastrectomy; Humans; Liver Neoplasms; Lymph Node Excision; Male; Middle Aged; Neoplasm Invasiveness; Stomach Neoplasms | 1994 |
[Adjuvant chemotherapy in infiltrating bladder carcinoma. Long-term results].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Epirubicin; Female; Follow-Up Studies; Humans; Male; Methotrexate; Middle Aged; Neoplasm Invasiveness; Survival Rate; Urinary Bladder Neoplasms; Vinblastine | 1993 |
[A case of giant advanced breast cancer responding remarkably to CEFT therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Middle Aged; Neoplasm Invasiveness; Tamoxifen; Thoracic Neoplasms | 1993 |
Intra-arterial chemotherapy for muscle-invasive urinary bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Epirubicin; Female; Humans; Infusions, Intra-Arterial; Male; Methotrexate; Middle Aged; Neoplasm Invasiveness; Tomography, Emission-Computed, Single-Photon; Urinary Bladder Neoplasms; Vinblastine | 1996 |
Successful treatment of intracaval and atrial extension of Wilms' tumour by chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Combined Modality Therapy; Dactinomycin; Epirubicin; Heart Atria; Humans; Kidney Neoplasms; Male; Neoplasm Invasiveness; Vena Cava, Inferior; Vincristine; Wilms Tumor | 1996 |
TP53 accumulation predicts improved survival in patients resistant to systemic cisplatin-based chemotherapy for muscle-invasive bladder cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drug Resistance, Multiple; Epirubicin; Female; Genes, p53; Humans; Male; Methotrexate; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Predictive Value of Tests; Prognosis; Retrospective Studies; Survival Rate; Tumor Suppressor Protein p53; Urinary Bladder Neoplasms; Vinblastine | 1999 |
Long term follow-up of combined radiochemotherapy for locally advanced bladder carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Epirubicin; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Invasiveness; Patient Compliance; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 2000 |
An evaluation of predictive factors involved in clinical or pathological response to primary chemotherapy in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Cyclophosphamide; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Logistic Models; Mastectomy, Segmental; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Probability; Prognosis; Survival Rate; Treatment Outcome | 2002 |
[A effective combination preoperative intraarterial infusion chemotherapy and irradiation for advanced sigmoid colon cancer with bladder invasion].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Epirubicin; Humans; Infusions, Intra-Arterial; Iodized Oil; Male; Middle Aged; Neoplasm Invasiveness; Preoperative Care; Sigmoid Neoplasms; Tegafur; Uracil; Urinary Bladder Neoplasms | 1992 |
Organ conservation in bladder cancer.
Topics: Administration, Intravesical; Combined Modality Therapy; Drug Administration Schedule; Epirubicin; Humans; Mitomycin; Neoplasm Invasiveness; Urinary Bladder Neoplasms | 1991 |